Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three IPOs, Three SPAC Mergers, But One Company Opted Out

Talaris, Valneva, Anebulo Make 43 US Biopharma IPOs In 2021

Executive Summary

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

You may also be interested in...



Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds

Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.

Finance Watch: Three Newly Public Companies Face Mixed Reception In Early Trading

Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.

Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88

Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel